P38MAPK is involved in apoptosis development in apheresis platelet concentrates after riboflavin and ultraviolet light treatment

Transfusion

Volumn 55, Issue 4, 2015, Pages 848-857

  Chen, Zhongming ^a,b   Schubert, Peter ^a,b,c   Culibrk, Brankica ^a,b   Devine, Dana V ^a,b,c  

^a CANADIAN BLOOD SERVICES   (Canada)

^b UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^c UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CASPASE 3; CASPASE 9; MITOGEN ACTIVATED PROTEIN KINASE P38; MYOSIN LIGHT CHAIN KINASE; PROTEIN BAK; PROTEIN BAX; PROTEIN BCL XL; RIBOFLAVIN; THROMBOCYTE CONCENTRATE; 4 (4 FLUOROPHENYL) 2 (4 METHYLSULFINYLPHENYL) 5 (4 PYRIDYL)IMIDAZOLE; APOPTOSIS REGULATORY PROTEIN; CASP3 PROTEIN, HUMAN; CASP9 PROTEIN, HUMAN; IMIDAZOLE DERIVATIVE; MAP-KINASE-ACTIVATED KINASE 2; PHOTOSENSITIZING AGENT; PROTEIN KINASE; PROTEIN KINASE INHIBITOR; PROTEIN SERINE THREONINE KINASE; PYRIDINE DERIVATIVE; SIGNAL PEPTIDE;

APOPTOSIS; ARTICLE; CONTROLLED STUDY; ENZYME INHIBITION; ENZYME PHOSPHORYLATION; GLUCOSE INTAKE; GLUCOSE METABOLISM; HUMAN; HUMAN CELL; IN VITRO STUDY; PH; PHOTOTHERAPY; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; THROMBOCYTOPHERESIS; ANTAGONISTS AND INHIBITORS; BLOOD; CYTOLOGY; DRUG EFFECTS; ENZYMOLOGY; PHOSPHORYLATION; PHYSIOLOGY; PROTEIN PROCESSING; RADIATION RESPONSE; THROMBOCYTE; ULTRAVIOLET RADIATION;

APOPTOSIS; APOPTOSIS REGULATORY PROTEINS; BLOOD PLATELETS; CASPASE 3; CASPASE 9; HUMANS; IMIDAZOLES; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; P38 MITOGEN-ACTIVATED PROTEIN KINASES; PHOSPHORYLATION; PHOTOSENSITIZING AGENTS; PROTEIN KINASE INHIBITORS; PROTEIN KINASES; PROTEIN PROCESSING, POST-TRANSLATIONAL; PROTEIN-SERINE-THREONINE KINASES; PYRIDINES; RIBOFLAVIN; SIGNAL TRANSDUCTION; ULTRAVIOLET RAYS;

EID: 84926462475     PISSN: 00411132     EISSN: 15372995     Source Type: Journal    
DOI: 10.1111/trf.12905     Document Type: Article

References (51)

1. Seghatchian J, de Sousa G,. Pathogen-reduction systems for blood components: the current position and future trends. Transfus Apher Sci 2006; 35: 189-196.
2. Hervig T, Seghatchian J, Apelseth TO,. Current debate on pathogen inactivation of platelet concentrates-to use or not to use? Transfus Apher Sci 2010; 43: 411-414.
3. Chakrabarty P, Rudra S, Hoque MM,. Update of pathogen reduction technology for therapeutic plasma. Mymensingh Med J 2010; 19: 308-311.
4. Picker SM,. Current methods for the reduction of blood-borne pathogens: a comprehensive literature review. Blood Transfus 2013; 11: 343-348.
5. Ruane PH, Edrich R, Gampp D, et al. Photochemical inactivation of selected viruses and bacteria in platelet concentrates using riboflavin and light. Transfusion 2004; 44: 877-885.
6. Goodrich RP, Gilmour D, Hovenga N, et al. A laboratory comparison of pathogen reduction technology treatment and culture of platelet products for addressing bacterial contamination concerns. Transfusion 2009; 49: 1205-1216.
7. Tonnetti L, Proctor MC, Reddy HL, et al. Evaluation of the Mirasol pathogen [corrected] reduction technology system against Babesia microti in apheresis platelets and plasma. Transfusion 2010; 50: 1019-1027.
8. Reddy HL, Doane SK, Keil SD, et al. Development of a riboflavin and ultraviolet light-based device to treat whole blood. Transfusion 2013; 53 (Suppl 1): 131S-136S.
9. Jackson SP, Schoenwaelder SM,. Procoagulant platelets: are they necrotic? Blood 2010; 116: 2011-2018.
10. Mason KD, Carpinelli MR, Fletcher JI, et al. Programmed anuclear cell death delimits platelet life span. Cell 2007; 128: 1173-1186.
11. Dowling MR, Josefsson EC, Henley KJ, et al. Platelet senescence is regulated by an internal timer, not damage inflicted by hits. Blood 2010; 116: 1776-1778.
12. Leytin V, Allen DJ, Mykhaylov S, et al. Thrombin-triggered platelet apoptosis. J Thromb Haemost 2006; 4: 2656-2663.
13. Leytin V, Allen DJ, Mutlu A, et al. Mitochondrial control of platelet apoptosis: effect of cyclosporin A, an inhibitor of the mitochondrial permeability transition pore. Lab Invest 2009; 89: 374-384.
14. Vogler M, Hamali HA, Sun XM, et al. BCL2/BCL-X(L) inhibition induces apoptosis, disrupts cellular calcium homeostasis, and prevents platelet activation. Blood 2011; 117: 7145-7154.
15. Perrotta PL, Perrotta CL, Snyder EL,. Apoptotic activity in stored human platelets. Transfusion 2003; 43: 526-535.
16. Kuter DJ,. Apoptosis in platelets during ex vivo storage. Vox Sang 2002; 83 (Suppl 1): 311-313.
17. Albanyan AM, Harrison P, Murphy MF,. Markers of platelet activation and apoptosis during storage of apheresis- and buffy coat-derived platelet concentrates for 7 days. Transfusion 2009; 49: 108-117.
18. Li J, Xia Y, Bertino AM, et al. The mechanism of apoptosis in human platelets during storage. Transfusion 2000; 40: 1320-1329.
19. Cookson P, Sutherland J, Turner C, et al. Platelet apoptosis and activation in platelet concentrates stored for up to 12 days in plasma or additive solution. Transfus Med 2010; 20: 392-402.
20. Bertino AM, Qi XQ, Li J, et al. Apoptotic markers are increased in platelets stored at 37 degrees C. Transfusion 2003; 43: 857-866.
21. Reid S, Johnson L, Woodland N, et al. Pathogen reduction treatment of buffy coat platelet concentrates in additive solution induces proapoptotic signaling. Transfusion 2012; 52: 2094-2103.
22. Schubert P, Coupland D, Culibrk B, et al. Riboflavin and ultraviolet light treatment of platelets triggers p38MAPK signaling: inhibition significantly improves in vitro platelet quality after pathogen reduction treatment. Transfusion 2013; 53: 3164-3173.
23. Schubert P, Thon JN, Walsh GM, et al. A signaling pathway contributing to platelet storage lesion development: targeting PI3-kinase-dependent Rap1 activation slows storage-induced platelet deterioration. Transfusion 2009; 49: 1944-1955.
24. Schubert P, Culibrk B, Coupland D, et al. Riboflavin and ultraviolet light treatment potentiates vasodilator-stimulated phosphoprotein Ser-239 phosphorylation in platelet concentrates during storage. Transfusion 2012; 52: 397-408.
25. Prudent M, D'Alessandro A, Cazenave JP, et al. Proteome changes in platelets after pathogen inactivation-an interlaboratory consensus. Transfus Med Rev 2014; 28: 72-83.
26. Prowse CV,. Component pathogen inactivation: a critical review. Vox Sang 2013; 104: 183-199.
27. Seltsam A, Muller TH,. Update on the use of pathogen-reduced human plasma and platelet concentrates. Br J Haematol 2013; 162: 442-454.
28. Goodrich RP, Edrich RA, Li J, et al. The Mirasol PRT system for pathogen reduction of platelets and plasma: an overview of current status and future trends. Transfus Apher Sci 2006; 35: 5-17.
29. Vanlandingham DL, Keil SD, Horne KM, et al. Photochemical inactivation of chikungunya virus in plasma and platelets using the Mirasol pathogen reduction technology system. Transfusion 2013; 53: 284-290.
30. Fast LD, Dileone G, Li J, et al. Functional inactivation of white blood cells by Mirasol treatment. Transfusion 2006; 46: 642-648.
31. Jocic M, Trkuljic M, Jovicic D, et al. Mirasol PRT system inactivation efficacy evaluated in platelet concentrates by bacteria-contamination model. Vojnosanit Pregl 2011; 68: 1041-1046.
32. Johnson GL, Lapadat R,. Mitogen-activated protein kinase pathways mediated by ERK, JNK, and p38 protein kinases. Science 2002; 298: 1911-1912.
33. Zanke BW, Boudreau K, Rubie E, et al. The stress-activated protein kinase pathway mediates cell death following injury induced by cis-platinum, UV irradiation or heat. Curr Biol 1996; 6: 606-613.
34. Raingeaud J, Gupta S, Rogers JS, et al. Pro-inflammatory cytokines and environmental stress cause p38 mitogen-activated protein kinase activation by dual phosphorylation on tyrosine and threonine. J Biol Chem 1995; 270: 7420-7426.
35. Leytin V, Freedman J,. Platelet apoptosis in stored platelet concentrates and other models. Transfus Apher Sci 2003; 28: 285-295.
36. Seghatchian J, Krailadsiri P,. Platelet storage lesion and apoptosis: are they related? Transfus Apher Sci 2001; 24: 103-105.
37. Shiri R, Yari F, Ahmadinejad M, et al. The caspase-3 inhibitor (peptide Z-DEVD-FMK) affects the survival and function of platelets in platelet concentrate during storage. Blood Res 2014; 49: 49-53.
38. Kralova J, Dvorak M, Koc M, et al. p38 MAPK plays an essential role in apoptosis induced by photoactivation of a novel ethylene glycol porphyrin derivative. Oncogene 2008; 27: 3010-3020.
39. Wada T, Penninger JM,. Mitogen-activated protein kinases in apoptosis regulation. Oncogene 2004; 23: 2838-2849.
40. Saklatvala J, Rawlinson L, Waller RJ, et al. Role for p38 mitogen-activated protein kinase in platelet aggregation caused by collagen or a thromboxane analogue. J Biol Chem 1996; 271: 6586-6589.
41. Kramer RM, Roberts EF, Um SL, et al. p38 mitogen-activated protein kinase phosphorylates cytosolic phospholipase A2 (cPLA2) in thrombin-stimulated platelets. Evidence that proline-directed phosphorylation is not required for mobilization of arachidonic acid by cPLA2. J Biol Chem 1996; 271: 27723-27729.
42. Kramer RM, Roberts EF, Strifler BA, et al. Thrombin induces activation of p38 MAP kinase in human platelets. J Biol Chem 1995; 270: 27395-27398.
43. Dangelmaier C, Jin J, Daniel JL, et al. The P2Y1 receptor mediates ADP-induced p38 kinase-activating factor generation in human platelets. Eur J Biochem 2000; 267: 2283-2289.
44. Franke TF, Hornik CP, Segev L, et al. PI3K/Akt and apoptosis: size matters. Oncogene 2003; 22: 8983-8998.
45. AuBuchon JP, Herschel L, Roger J, et al. Efficacy of apheresis platelets treated with riboflavin and ultraviolet light for pathogen reduction. Transfusion 2005; 45: 1335-1341.
46. Cazenave JP, Follea G, Bardiaux L, et al. A randomized controlled clinical trial evaluating the performance and safety of platelets treated with MIRASOL pathogen reduction technology. Transfusion 2010; 50: 2362-2375.
47. Canault M, Duerschmied D, Brill A, et al. p38 mitogen-activated protein kinase activation during platelet storage: consequences for platelet recovery and hemostatic function in vivo. Blood 2010; 115: 1835-1842.
48. Rukoyatkina N, Mindukshev I, Walter U, et al. Dual role of the p38 MAPK/cPLA2 pathway in the regulation of platelet apoptosis induced by ABT-737 and strong platelet agonists. Cell Death Dis 2013; 4: e931.
49. van Delft MF, Wei AH, Mason KD, et al. The BH3 mimetic ABT-737 targets selective Bcl-2 proteins and efficiently induces apoptosis via Bak/Bax if Mcl-1 is neutralized. Cancer Cell 2006; 10: 389-399.
50. Weyrich AS, Dixon DA, Pabla R, et al. Signal-dependent translation of a regulatory protein, Bcl-3, in activated human platelets. Proc Natl Acad Sci U S A 1998; 95: 5556-5561.
51. Brogren H, Karlsson L, Andersson M, et al. Platelets synthesize large amounts of active plasminogen activator inhibitor 1. Blood 2004; 104: 3943-3948.